藍光發展(600466.SH):成都迪康藥業100%股權交割已完成
格隆匯10月22日丨藍光發展(600466.SH)公佈,公司及藍迪共享擬以9億元為對價將合計持有的成都迪康藥業股份有限公司(以下簡稱“標的公司”)100%的股權轉讓給漢商集團和漢商大健康,交易作價為9億元。
2020年10月20日,公司、藍迪共享已將其持有的標的公司100%股份轉移至漢商集團及其子公司漢商大健康名下,標的公司股份交割已經完成。根據本次交易《股份轉讓協議》及其補充協議的約定,漢商集團及其子公司漢商大健康將在標的公司股份交割後5個工作日內,完成第一期轉讓價款的支付;並於2021年5月31日前完成第二期轉讓價款的支付。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.